PMV Pharmaceuticals

Company snapshot

MV Pharmaceuticals was a private drug discovery R&D organization that utilized leading-edge technologies and innovative practices to develop revolutionary scientific advancements within medicine that are projected to save more than 7 billion lives. Drug discovery operations resulted in 35 patented drugs and 65 additional market-suitable pharmaceutical compounds | forecasting indicates annual reven

• 6 active pipeline program(s) linked via ClinicalTrials.gov.
• 11 US patent(s) indexed to this assignee profile.
• 6 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for PMV Pharmaceuticals. Not investment advice.

• Peer + 0 momentum

  Aprea Therapeutics

  TA overlap score 23

Recent activity

Latest pipeline, patent, and corporate events for PMV Pharmaceuticals.

1. Jun 8, 2026 Clinical update

   metformin hydrochloride 500 mg tablet — Phase 1

2. May 26, 2026 Clinical update

   PC14586 — Phase 2

3. May 23, 2026 Clinical update

   rezatapopt — Phase 2

4. May 23, 2026 Clinical update

   Azacitidine — Phase 1

5. May 23, 2026 Clinical update

   PC14586 — Phase 1

View all clinical trial activity →

• What is PMV Pharmaceuticals?

  MV Pharmaceuticals is a pharma organization headquartered in PRINCETON, NJ, USA. It trades on NYSE under ticker PMVP. Primary therapeutic focus areas include Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation, Myelodysplastic Syndrome, TP53 Y220C Mutation

• Is PMV Pharmaceuticals publicly traded?

  Yes. PMV Pharmaceuticals is listed with ticker PMVP on NYSE per SEC EDGAR records linked on this profile.

• What drugs does PMV Pharmaceuticals develop or market?

  We link 5 drug profile(s) where PMV Pharmaceuticals is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/pmv-pharmaceuticals#company-drugs.

• What are the latest developments for PMV Pharmaceuticals?

  In the last 12 months our linked public records show 6 trial program update(s) and 2 US patent grant(s) tied to this profile.

• What therapeutic areas does PMV Pharmaceuticals focus on?

  PMV Pharmaceuticals focuses on Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation, Myelodysplastic Syndrome, TP53 Y220C Mutation based on our analysis of their pipeline programs and drug development activities.